The Differential Effects of Anti-Diabetic Thiazolidinedione on Prostate Cancer Progression Are Linked to the TR4...

Area of Science:

• Endocrinology
• Oncology
• Molecular Biology

Background:

• Thiazolidinediones (TZDs) are insulin sensitizers targeting peroxisome proliferator-activated receptors (PPARs).
• Previous concerns regarding TZD side effects led to market restrictions.
• The role of TZDs in prostate cancer (PCa) progression remains unclear.

Purpose of the Study:

• To investigate the impact of TZDs on prostate cancer (PCa) progression.
• To explore the association between TR4 nuclear receptor expression and TZD effects in PCa.
• To elucidate the molecular mechanisms underlying TZD-mediated effects on PCa.

Main Methods:

• Analysis of TR4 nuclear receptor expression in PCa patient tumors.
• In vitro studies using PCa cell lines with varying TR4 expression (knockdown vs. wild type).
• Assessment of cell growth, invasion, and oncogene expression (HRAS) following TZD treatment.

Main Results:

• A subset of PCa patients (9%) exhibited TR4 allele deletion in tumors.
• TZD treatment promoted PCa cell growth and invasion in cells with TR4 knockdown.
• Conversely, TZD treatment inhibited PCa progression in cells with wild-type TR4.
• TZD treatment upregulated the Harvey Rat Sarcoma (HRAS) oncogene in TR4-knockdown cells.
• Inhibition of HRAS reversed TZD-induced PCa progression.

Conclusions:

• TZD's effect on PCa progression is dependent on TR4 nuclear receptor expression status.
• TR4 deletion may indicate a higher risk of TZD-induced PCa progression.
• Clinical caution is advised for diabetic PCa patients with TR4 allele deletion receiving TZD therapy.